Views & Analysis Creating headroom: can cutting spend on low-value prescripti... Can reducing NHS spending on 'low-value' prescriptions help fund new drugs?
News After rebuffing Biogen, Sage pairs off with Supernus Sage Therapeutics has agreed to be acquired by Supernus Pharma in a deal valued at around $571 million.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
